Spectrum Pharmaceuticals Announces FDA's Acceptance of Ozarelix IND and Approval of Phase 2b Protocol in BPH (Benign ... (PR Newswire via Yahoo! Finance)
Spectrum Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has accepted the Company's Investigational New Drug application for ozarelix in Benign Prostate Hypertrophy and that the FDA has approved the protocol for the Phase 2b study of ozarelix for the treatment of BPH.

I-Flow Announces That Medicare Now Covers ON-Q(R) under Hospital Outpatient Payment System (Business Wire via Yahoo! Finance)
LAKE FOREST, Calif.----I-Flow Corporation announced that effective January 1, 2007 Medicare covers ON-Q to treat post-surgical pain under the hospital outpatient payment system .